PreDxion Bio
Rapid, scalable diagnostic for SARS-CoV-2 and beyond
What PreDxion Bio does
PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale. PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about PreDxion Bio yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.